Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI North America CPhI North America
Not Confirmed
Not Confirmed
20-22 May, 2025
STLE Annual MeetingSTLE Annual Meeting
Not Confirmed
Not Confirmed
18-22 May, 2025
American Thoracic Soci...American Thoracic Society
Not Confirmed
Not Confirmed
18-21 May, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
STLE Annual MeetingSTLE Annual Meeting
Industry Trade Show
Not Confirmed
18-22 May, 2025
American Thoracic Soci...American Thoracic Society
Industry Trade Show
Not Confirmed
18-21 May, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/dmf-filings-surge-44-in-q1-2025-india-tops-list-with-51-rise-in-year-on-year-submissions
14 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/14/3080987/0/en/Foghorn-Therapeutics-Provides-First-Quarter-2025-Financial-and-Corporate-Update.html
05 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/05/3073936/0/en/Foghorn-Therapeutics-to-Participate-in-the-Citizens-Life-Sciences-Conference.html
01 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/01/3072208/0/en/Foghorn-Therapeutics-Appoints-Neil-Gallagher-and-Stuart-Duty-to-its-Board-of-Directors.html
28 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/28/3069635/0/en/Foghorn-Therapeutics-Presents-New-Preclinical-Data-on-Selective-SMARCA2-Inhibitor-FHD-909-and-Selective-CBP-and-Selective-EP300-Degrader-Programs-and-Provides-Pipeline-Update.html
15 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/15/3061552/0/en/Foghorn-Therapeutics-to-Host-Virtual-Investor-Event-to-Review-Pipeline-Updates-in-Conjunction-with-2025-AACR-Annual-Meeting.html
25 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/25/3049200/0/en/Foghorn-Therapeutics-Announces-New-Preclinical-Data-for-Selective-SMARCA2-Inhibitor-FHD-909-and-Selective-CBP-and-EP300-Degrader-Programs-at-2025-AACR-Meeting.html
Details:
FHD-286 is a highly potent, first-in-class, selective, allosteric, and orally available small-molecule, enzymatic inhibitor of SMARCA2 (BRM) and SMARCA4 (BRG1) was being investigated for R/R AML.
Lead Product(s): FHD-286,Decitabine
Therapeutic Area: Oncology Brand Name: FHD-286
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 16, 2024
Lead Product(s) : FHD-286,Decitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Foghorn Therapeutics Provides Update On FHD-286 Clinical Development
Details : FHD-286 is a highly potent, first-in-class, selective, allosteric, and orally available small-molecule, enzymatic inhibitor of SMARCA2 (BRM) and SMARCA4 (BRG1) was being investigated for R/R AML.
Product Name : FHD-286
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 16, 2024
Details:
FHD-909 is a first-in-class oral BRM selective inhibitor. It is being evaluated in preclinical studies for the treatment of BRG1 mutated non-small cell lung cancer.
Lead Product(s): FHD-909
Therapeutic Area: Oncology Brand Name: FHD-909
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Eli Lilly
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 10, 2024
Foghorn Doses First Patient with SMARCA2 Inhibitor For Solid Tumors
Details : FHD-909 is a first-in-class oral BRM selective inhibitor. It is being evaluated in preclinical studies for the treatment of BRG1 mutated non-small cell lung cancer.
Product Name : FHD-909
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 10, 2024
Details:
FHD-909 is a first-in-class oral BRM selective inhibitor. It is being evaluated in preclinical studies for the treatment of BRG1 mutated non-small cell lung cancer.
Lead Product(s): FHD-909
Therapeutic Area: Oncology Brand Name: FHD-909
Study Phase: PreclinicalProduct Type: Other Small Molecule
Sponsor: Eli Lilly
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 02, 2024
Lead Product(s) : FHD-909
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
Details : FHD-909 is a first-in-class oral BRM selective inhibitor. It is being evaluated in preclinical studies for the treatment of BRG1 mutated non-small cell lung cancer.
Product Name : FHD-909
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 02, 2024
Details:
The net proceeds will be used to advance the clinical development of FHD-286, a selective, oral inhibitor of BRG1 and BRM, which is being evaluated in relapsed/refractory AML
Lead Product(s): FHD-286,Cytarabine
Therapeutic Area: Oncology Brand Name: FHD-286
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: BVF Partners
Deal Size: $110.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 22, 2024
Lead Product(s) : FHD-286,Cytarabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : BVF Partners
Deal Size : $110.0 million
Deal Type : Public Offering
Foghorn Therapeutics Raises $110 Million Through Direct Offering to Advance Pipeline
Details : The net proceeds will be used to advance the clinical development of FHD-286, a selective, oral inhibitor of BRG1 and BRM, which is being evaluated in relapsed/refractory AML
Product Name : FHD-286
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 22, 2024
Details:
FHD-286 is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM. In preclinical studies, FHD-286 has shown anti-tumor activity for broad range of malignancies.
Lead Product(s): FHD-286,Cytarabine
Therapeutic Area: Oncology Brand Name: FHD-286
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 01, 2023
Lead Product(s) : FHD-286,Cytarabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FHD-286 is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM. In preclinical studies, FHD-286 has shown anti-tumor activity for broad range of malignancies.
Product Name : FHD-286
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 01, 2023
Details:
FHD-286 is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM, which is investigated for the treatment of relapsed and/or refractory acute myelogenous leukemia.
Lead Product(s): FHD-286,Cytarabine
Therapeutic Area: Oncology Brand Name: FHD-286
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 31, 2023
Lead Product(s) : FHD-286,Cytarabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FHD-286 is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM, which is investigated for the treatment of relapsed and/or refractory acute myelogenous leukemia.
Product Name : FHD-286
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 31, 2023
Details:
FHD-286 is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM, which is investigated for the treatment of Metastatic Uveal Melanoma.
Lead Product(s): FHD-286
Therapeutic Area: Oncology Brand Name: FHD-286
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 28, 2023
Details : FHD-286 is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM, which is investigated for the treatment of Metastatic Uveal Melanoma.
Product Name : FHD-286
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2023
Details:
FHD-286 is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM. FDA has lifted the clinical hold on the Phase 1 monotherapy dose escalation study of FHD-286 in AML and MDS.
Lead Product(s): FHD-286,Cytarabine
Therapeutic Area: Oncology Brand Name: FHD-286
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 06, 2023
Lead Product(s) : FHD-286,Cytarabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FHD-286 is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM. FDA has lifted the clinical hold on the Phase 1 monotherapy dose escalation study of FHD-286 in AML and MDS.
Product Name : FHD-286
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 06, 2023
Details:
FHD-609 breaks down a protein called BRD9 that can turn on other groups of proteins and promote the growth of cancer cells. Stopping BRD9 from acting on these other proteins may stop the growth of new cancer cells.
Lead Product(s): FHD-609
Therapeutic Area: Oncology Brand Name: FHD-609
Study Phase: Phase IProduct Type: PROTACs
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 24, 2023
Foghorn Therapeutics Provides an Update on FHD-609
Details : FHD-609 breaks down a protein called BRD9 that can turn on other groups of proteins and promote the growth of cancer cells. Stopping BRD9 from acting on these other proteins may stop the growth of new cancer cells.
Product Name : FHD-609
Product Type : PROTACs
Upfront Cash : Inapplicable
April 24, 2023
Details:
FHD-609 is a potent, selective, intravenously administered protein degrader of BRD9, a component of the ncBAF complex, initially being developed for synovial sarcoma and SMARCB1-loss tumors.
Lead Product(s): FHD-609
Therapeutic Area: Oncology Brand Name: FHD-609
Study Phase: Phase IProduct Type: PROTACs
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 26, 2022
Details : FHD-609 is a potent, selective, intravenously administered protein degrader of BRD9, a component of the ncBAF complex, initially being developed for synovial sarcoma and SMARCB1-loss tumors.
Product Name : FHD-609
Product Type : PROTACs
Upfront Cash : Inapplicable
October 26, 2022
ABOUT THIS PAGE